Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 for Optical Imaging in Pediatric Brain Tumors
NCT04085887Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in brain tumor, sponsored by Stanford University. Planned start Dec 2026; status: recruiting.
02
Drugs
panitumumab
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT04085887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085887.